Herceptin

Handbook of Experimental Pharmacology

Volumn 181, Issue , 2008, Pages 183-219

  Shepard, H M ^a   Jin, P ^a   Slamon, D J ^b   Pirot, Z ^a   Maneval, D C ^a  

^a Receptor BioLogix Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANIMAL; BREAST TUMOR; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; FEMALE; HISTORY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; PATHOLOGY; PROTEIN CONFORMATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DESIGN; EPIDERMAL GROWTH FACTOR; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOTHERAPY; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 38449098401     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-540-73259-4_9     Document Type: Article

References (135)

1. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M (1988) Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80:1605-1611
2. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX (2005) Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55:717-727
3. Ajani JA, Randolph HJ, Ho L, Baker J, Oortgiesen M, Eduljee A, Michaeli D (2006) An openlabel, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer 106:1908-1916
4. AloysiusMM, Robins RA, Eremin JM, Eremin O (2006) Vaccination therapy in malignant disease. Surgeon 4:309-320
5. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B (2006) Trastuzumab-based treatment of HER2- positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94:259-267
6. Ashrafian H (2006) Cancers sweet tooth: the Janus effect of glucose metabolism in tumorigenesis. Lancet 367:618-621
7. Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G (2004) Alpha-particle emitting atomic generator (Actinium-225)- labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res 10:4489-4497
8. Baselga J (2001) Clinical trials of Herceptin(R) (trastuzumab). Eur J Cancer 37 Suppl 1:18-24
9. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti- HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831
10. Baselga J, Perez EA, Pienkowski T, Bell R (2006) Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11 Suppl 1:4-12
11. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744
12. Berezov A, Greene MI, Murali R (2003) Structure-based approaches to inhibition of erbB receptors with peptide mimetics. Immunol Res 27:303-308
13. Bianchi S, Palli D, Falchetti M, Saieva C, Masala G, Mancini B, Lupi R, Noviello C, Omerovic J, Paglierani M, Vezzosi V, Alimandi M, Mariani-Costantini R, Ottini L (2006) ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study. J Cell Physiol 206: 702-708
14. Bishop JM (1989) Nobel Prize Lecture: Retroviruses and Oncogenes II
15. Blumenthal RD, Sharkey RM, Goldenberg DM (1990) Current perspectives and challenges in the use of monoclonal antibodies as imaging and theraputic agents. Adv Drug Deliv Rev 4:279-318
16. Brechbiel MW,Waldmann TA (2000) Anti-HER2 radioimmunotherapy. Breast Dis 11:125-132
17. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12:541-552
18. Carter P, Fendly BM, Lewis GD, Sliwkowski MX (2000) Development of herceptin. Breast Dis 11:103-111
19. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D,WongWL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289
20. Chazin VR, Kaleko M, Miller AD, Slamon DJ (1992) Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7:1859-1866
21. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS (2001) Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7:1957-1962
22. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505-516
23. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648
24. Cohen BD, Kiener PA, Green JM, Foy L, Fell HP, Zhang K (1996) The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J Biol Chem 271:30897-30903
25. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139
26. Crow DM,Williams L, Colcher D,Wong JY, Raubitschek A, Shively JE (2005) Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol. Bioconjug Chem 16:1117-1125
27. De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D, Press O (1992) Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 52:1916-1923
28. Doherty JK, Bond C, Jardim A, Adelman JP, Clinton GM(1999) The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci USA 96:10869-10874
29. Dorr RT, Von Hoff DD (1994) Cancer Chemotherapy Handbook., 2nd edn. Appleton and Lange, Norwalk, pp 500-515
30. Drebin JA, Link VC, Stern DF,Weinberg RA, Greene MI (1985) Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:697-706
31. Fendly BM, Kotts C, Vetterlein D, Lewis GD,Winget M, Carver ME,Watson SR, Sarup J, Saks S, Ullrich A (1990a) The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J Biol Response Mod 9:449-455
32. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A (1990b) Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50:1550-1558
33. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611
34. Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y (2005) Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci USA 102:1915-1920
35. Garratt AN (2006) "To erb-B or not to erb-B. . . " Neuregulin-1/ErbB signaling in heart development and function. J Mol Cell Cardiol 41:215-218
36. Ghatak S, Misra S, Toole BP (2005) Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem 280:8875-8883
37. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, McLeod C, Mendelsohn J (1984) Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259: 7755-7760
38. Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, Comoglio PM (1989) Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 339:155-156
39. Goldenberg DM (1991) Challenges to the therapy of cancer with monoclonal antibodies. J Natl Cancer Inst 83:78-79
40. Goldenberg DM, Sharkey RM (2006) Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imag 50:248-264
41. Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH, Bakshi K, Kamins J, Borgmann- Winter KE, Siegel SJ, Gallop RJ, Arnold SE (2006) Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12:824-828
42. Hall D, Gogos JA, Karayiorgou M(2004) The contribution of three strong candidate schizophrenia susceptibility genes in demographically distinct populations. Genes Brain Behav 3:240-248
43. Heidelberger C, Chaudhuri Nk, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer Rj, Pleven E, Scheiner J (1957) Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179:663-666
44. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD (1992) Identification of heregulin, a specific activator of p185erbB2. Science 256:1205-1210
45. Hommelgaard AM, Lerdrup M, van DB (2004) Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 15:1557-1567
46. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M (2005) Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23:712-719
47. Hudziak RM, Lewis GD, HolmesWE, Ullrich A, Shepard HM (1990) Selection for transformation and met protooncogene amplification in NIH 3T3 fibroblasts using tumor necrosis factor alpha. Cell Growth Differ 1:129-134
48. Hudziak RM, Lewis GD, Shalaby MR, Eessalu TE, Aggarwal BB, Ullrich A, Shepard HM (1988) Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. Proc Natl Acad Sci USA 85:5102-5106
49. Hudziak RM, Lewis GD,Winget M, Fendly BM, Shepard HM, Ullrich A (1989) p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165-1172
50. Hudziak RM, Schlessinger J, Ullrich A (1987) Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84:7159-7163
51. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354
52. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, Miyoshi E, Monden M, Matsuura N (2001) Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 84:1377-1383
53. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkio S, Flander M, Helle L, Ingalsuo S, Johansson K, Jaaskelainen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820
54. Katoh M, Yazaki Y, Sugimura T, Terada M (1993) c-erbB3 gene encodes secreted as well as transmembrane receptor tyrosine kinase. Biochem Biophys Res Commun 192:1189-1197
55. King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974-976
56. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639
57. Kotts CE, Su FM, Leddy C, Dodd T, Scates S, Shalaby MR, Wirth CM, Giltinan D, Schroff RW, Fritzberg AR, Shepard HM, Slamon DJ, Hutchins BM (1996) 186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts. Cancer Biother Radiopharm 11:133-144
58. Kris RM, Lax I, GullickW,Waterfield MD, Ullrich A, Fridkin M, Schlessinger J (1985) Antibodies against a synthetic peptide as a probe for the kinase activity of the avian EGF receptor and v-erbB protein. Cell 40:619-625
59. Kumar PS, Pegram M (2006) Targeting HER2 Epitopes. Semin Oncol 33:386-391
60. Lackey DB, Groziak MP, Sergeeva M, Beryt M, Boyer C, Stroud RM, Sayre P, Park JW, Johnston P, Slamon D, Shepard HM, Pegram M (2001) Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. Biochem Pharmacol 61:179-189
61. Leibovich SJ, Polverini PJ, Shepard HM,Wiseman DM, Shively V, Nuseir N (1987) Macrophageinduced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 329:630-632
62. Lewis GD, Aggarwal BB, Eessalu TE, Sugarman BJ, Shepard HM (1987) Modulation of the growth of transformed cells by human tumor necrosis factor-alpha and interferon-gamma. Cancer Res 47:5382-5385
63. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM (1993) Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263
64. Leyland-Jones B (2001) Dose scheduling-Herceptin. Oncology 61 Suppl 2:31-36
65. Li Q, Boyer C, Lee JY, Shepard HM (2001) A novel approach to thymidylate synthase as a target for cancer chemotherapy. Mol Pharmacol 59:446-452
66. Makhija, Glenn D, Ueland F, Gold M, Dizon D, Paton V, Birkner M, Lin C, Derynck M, Matulonis U (2007) Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. J Clin Oncol 25:5507
67. Maneval DC, Baughman S, Hutchins B, Mordenti J (1991a) Pharmacokinetics of MuMab4D5 in cynomolgus monkeys. Pharm Res 8:54
68. Maneval DC, Hutchins B, Osaka G, Leddy C, Kotts C, Mohler M, Lewis D, Hansen S, Terrell T, Dodd T, Beaumier P, Giltinan D, Shalaby R, Stagg R, Mordenti J, Green J, Fritzberg A, Su FM (1993) Studies with a radiolabeled humanized anti-p185HER2 monoclonal antibody (rhuMab HER2) in tumor-bearing mice. Antibody Immunoconjugates and Radiopharmaceuticals 6:80
69. Maneval DC, Hutchins B, Osaka G, Leddy C, Kotts C, Vetterlein D, Dodd T, Axworthy D, Beaumeier P, Vanderheyden JL, Shalaby R, Shepard HM, Mordenti J, Fritzberg A, Su FM (1992) Comparative evaluation of I-125 and Re-186 labeled murine anti-p185HER2 antibody (muMAb 4D5) in an animal tumor model. J Nucl Med 33:934
70. Maneval DC, Mordenti J, Hutchins B, Scates S, Hansen S, Keith D, Kotts C, Fletcher B, Fendly B, Blank G, Vetterlein D, Slamon D, Shepard HM, Green JD (1991b) Pharmacokinetics and whole body autoradiography of I-125 muMAb 4D5 in mice. J Nucl Med 32:1837
71. Maneval DC, Thomas D, Mordenti J, Green J (1991c) Utilization of interspecies scaling techniques to support dose selection in the development of a monoclonal antibody in GN 1445. The Toxicologist 11:235
72. Maple L, Lathrop R, Bozich S, Harman W, Tacey R, Kelley M, nilkovitch-Miagkova A (2004) Development and validation of ELISA for herceptin detection in human serum. J Immunol Methods 295:169-182
73. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, OByrne K, Conte P, Green M, Ward C, Mayne K, Extra JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265-4274
74. Meeks TW, Ropacki SA, Jeste DV (2006) The neurobiology of neuropsychiatric syndromes in dementia. Curr Opin Psychiat 19:581-586
75. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, Brechbiel MW (2005) Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 20:557-568
76. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, Brechbiel MW (2004) Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 10:7834-7841
77. Mitchell MS (2003) Combinations of anticancer drugs and immunotherapy. Cancer Immunol Immunother 52:686-692
78. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115
79. Muraoka-Cook RS, Sandahl M, Husted C, Hunter D,Miraglia L, Feng SM, Elenius K, Earp HS, III (2006) The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Mol Biol Cell 17:4118-4129
80. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ (2006) Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269-280
81. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I receptor/ human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118-11128
82. Nash PT, Florin TH (2005) Tumour necrosis factor inhibitors. Med J Aust 183:205-208
83. Nawa H, Takei N (2006) Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res 56:2-13
84. Nelson MH, Dolder CR (2006) Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40:261-269
85. Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, Li L, Press MF, Gambhir SS,Williams LE, Wong JY, Raubitschek AA, Shively JE, Wu AM (2005) Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 65:5907-5916
86. Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, OReilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS (2004) Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 10:136-143
87. Park JW, Stagg R, Lewis GD, Carter P, Maneval D, Slamon DJ, Jaffe H, Shepard HM (1992) Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. Cancer Treat Res 61:193-211
88. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ (1997) The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-547
89. Pegram MD, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251
90. Pegram MD, Konecny GE, OCallaghan C, Beryt M, Pietras R, Slamon DJ (2004) Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739-749
91. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671
92. Perik PJ, Lub-De Hooge MN, Gietema JA, Van der Graaf WT, de Korte MA, Jonkman S, Kosterink JG, Van Veldhuisen DJ, Sleijfer DT, Jager PL, De Vries EG (2006) Indium-111- labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24:2276-2282
93. Persson MI, Gedda L, Jensen HJ, Lundqvist H, Malmstrom PU, Tolmachev V (2006) Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours. Oncol Rep 15:673-680
94. Persson MI, Tolmachev V, Andersson K, Gedda L, Sandstrom M, Carlsson J (2005) [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging 32:1457-1462
95. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672
96. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ (1994) Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-1838
97. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ (1998) Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17:2235-2249
98. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467
99. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11-31
100. Qian X, ORourke DM, Zhao H, Greene MI (1996) Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein. Oncogene 13:2149-2157
101. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786-2792
102. Robinson AG, Turbin D, Thomson T, Yorida E, Ellard S, Bajdik C, Huntsman D, Gelmon K (2006) Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease. Clin Breast Cancer 7:254-261
103. Rohrbach S, Niemann B, Silber RE, Holtz J (2005) Neuregulin receptors erbB2 and erbB4 in failing human myocardium - depressed expression and attenuated activation. Basic Res Cardiol 100:240-249
104. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684
105. Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, Ullrich A, Coussens L (1985) The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229:976-978
106. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513-516
107. Semba K, Kamata N, Toyoshima K, Yamamoto T (1985) A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82:6497-6501
108. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437-441
109. Shak S (1999) Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 26:71-77
110. Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA, Jr., Ullrich A (1991) Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 11:117-127
111. Shih C, Padhy LC, Murray M, Weinberg RA (1981) Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290:261-264
112. Slamon D, Pegram M(2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28:13-19
113. Slamon DJ, Clark GM,Wong SG, LevinWJ, Ullrich A,McGuireWL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
114. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
115. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
116. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM (2004) Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22:701-706
117. Sosman JA, Sondak VK (2003) Melacine: an allogeneic melanoma tumor cell lysate vaccine. Expert Rev Vaccines 2:353-368
118. Sporn MB, Todaro GJ (1980) Autocrine secretion and malignant transformation of cells. N Engl J Med 303:878-880
119. Sugarman BJ, Lewis GD, Eessalu TE, Aggarwal BB, Shepard HM (1987) Effects of growth factors on the antiproliferative activity of tumor necrosis factors. Cancer Res 47:780-786
120. Tokuda Y, Ohnishi Y, Shimamura K, Iwasawa M, Yoshimura M, Ueyama Y, Tamaoki N, Tajima T, Mitomi T (1996) In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 73:1362-1365
121. Urban JL, Schreiber H (1988) Host-tumor interactions in immunosurveillance against cancer. Prog Exp Tumor Res 32:17-68
122. Urban JL, Shepard HM, Rothstein JL, Sugarman BJ, Schreiber H (1986) Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci USA 83:5233-5237
123. Varmus HE (1989) Nobel Prize Lecture: Retroviruses and Oncogenes I
124. Vidal GA, Naresh A, Marrero L, Jones FE (2005) Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. J Biol Chem 280:19777-19783
125. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726
126. Wang Y, Kristensen GB, Helland A, Nesland JM, Borresen-Dale AL, Holm R (2005) Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol 124:392-401
127. Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI (1989) A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 339:230-231
128. Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG (2005) Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 103:1770-1777
129. Witkop B (1999) Paul Ehrlich and his Magic bullets-revisited. Proc Am Philos Soc 143:540-557
130. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137
131. Yarden Y, Ullrich A (1988) Growth factor receptor tyrosine kinases. Annu Rev Biochem 57: 443-478
132. Yeon CH, Pegram MD (2005) Anti-erbB-2 antibody trastuzumab in the treatment of HER2- amplified breast cancer. Invest New Drugs 23:391-409
133. Zanazzi G, Einheber S, Westreich R, Hannocks MJ, Bedell-Hogan D, Marchionni MA, Salzer JL (2001) Glial growth factor/neuregulin inhibits Schwann cell myelination and induces demyelination. J Cell Biol 152:1289-1299
134. Zhang K, Sun J, Liu N, Wen D, Chang D, Thomason A, Yoshinaga SK (1996) Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem 271:3884-3890
135. Zhou W, Carpenter G (2002) ErbB-4: a receptor tyrosine kinase. Inflamm Res 51:91-101